QTX3034 in Patients With KRAS G12D Mutation
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.
Solid Tumors
DRUG: QTX3034|COMBINATION_PRODUCT: Cetuximab
Number of participants with Dose Limiting Toxicities (DLTs), DLTs will be defined as the occurrence of any of the toxicities as described in the protocol, up to 21 days|Number of participants with Treatment-emergent Adverse Events (TEAEs), Defined as adverse events reported for the first time or worsening of a pre-existing event after first dose of study drug monotherapy and in combination with cetuximab, up to 2 years
QTX3034 pharmacokinetic parameters in plasma, Plasma concentration data for QTX3034 will be used to evaluate PK parameters such as maximum concentration (Cmax), minimum concentration (Cmin), time to attain Cmax (Tmax), area under the concentration-time curve (AUC), elimination half-life (t1‚ÅÑ2)., up to 2 years|Objective response rate (ORR), The ORR is defined as the proportion of patients with a best overall response of complete response (CR) or partial response (PR) based on RECIST 1.1., up to 2 years|Duration of response (DOR), Duration of response (DoR) is defined as the time between first evidence of objective response and disease progression (as measured by RECIST 1.1) or death, whichever occurs earlier, in subjects who achieve CR or PR., up to 2 years
Phase 1 study to determine the safety and tolerability of QTX3034 as a single agent or in combination with cetuximab.